Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
Daraxonrasib showed significant survival gain in patients with metastatic pancreatic cancer and may redefine treatment after chemotherapy failure
A scientific presentation of great impact marked the plenary session of the American Society of Clinical Oncology (ASCO), held in Chicago, United States, on June 1, 2026.
Final data from the RASolute 302 study revealed that daraxonrasib, a pill administered once a day, nearly doubled the survival of patients with metastatic pancreatic cancer who no longer responded to conventional chemotherapy.
Results presented by Revolution Medicines were obtained in a phase 3 randomized clinical trial, considered the highest level of evidence before the adoption of new medical protocols.
-
New Fiat EV, priced at R$ 77,000, will bring a reinterpretation of the 147 and a consumption equivalent to 70 km/l.
-
Can a driver install LED headlights in any car? The replacement, which promises greater light range, energy savings, and durability, has become the target of technical restrictions due to the risk of glare in vehicles that did not come from the factory with the technology.
-
The wheelbarrow that seems to defy physics: artificial intelligence reduces by up to 90% the effort needed to move loads of up to 200 kg.
-
An American oil giant drilled a well nearly 6 kilometers deep and, in just 18 days, tapped into the underground heat that will be converted into clean energy.
Phase 3 study establishes new milestone in treatment
Researchers followed 500 patients, randomly distributed between two groups.
Some participants received daraxonrasib. The control group remained under treatment with conventional chemotherapy.
Such methodologies are used to eliminate external interferences and ensure that the observed benefits are directly related to the drug being investigated.
Patients with the RAS G12 mutation, one of the most frequent in pancreatic cancer, achieved a median survival of 13.2 months with the new treatment.
Median survival in the group treated with chemotherapy remained at 6.6 months.
Data presented during ASCO also indicated a 60% reduction in the risk of death, a result considered highly relevant by the specialists involved in the study.
Tumor reduction and lower interruption rate draw attention
Time to disease progression reached 7.3 months among patients treated with daraxonrasib.
The group subjected to chemotherapy showed an average of 3.5 months, practically half the period observed with the new drug.
More than 31% of patients treated with the pill recorded measurable tumor reduction.
The rate observed in the chemotherapy group was 11.2%.
Safety profile also drew attention during the presentation of the results.
Only 1.2% of participants discontinued treatment due to adverse effects.
The percentage recorded in the chemotherapy group reached 11.2%.
Conclusions published in the Journal of Clinical Oncology indicate that daraxonrasib has the potential to become the new second-line therapeutic standard for patients with metastatic pancreatic cancer.
RAS protein remains one of the biggest challenges in oncology
Pancreatic cancer is among the most aggressive tumors in modern medicine.
Diagnoses usually occur in advanced stages because the disease often progresses without evident symptoms during the initial phases.
Statistics cited by researchers indicate about 60,000 new cases per year in the United States, accompanied by approximately 50,000 annual deaths.
The Brazilian territory records approximately 13,000 new diagnoses and about 12,000 deaths related to the disease every year.
A large part of this difficulty is associated with the RAS protein, present in more than 90% of pancreatic tumors.
Mutations in this protein maintain continuous cell growth signals, favoring cancer progression.
Decades of research have attempted to block this mechanism. Satisfactory results, however, remained out of reach for a long time.
Regulatory approval will be the next step for the drug
Revolution Medicines confirmed that it intends to submit the results to the Food and Drug Administration (FDA), the United States regulatory agency.
Status of Breakthrough Therapy, orphan drug designation, and inclusion in priority review programs have already been granted to the treatment.
The Brazilian market still depends on future evaluations by Anvisa for potential approval.
Coverage by health plans would also require further analysis by the National Supplementary Health Agency (ANS).
High costs of modern oncology therapies represent another challenge for future incorporation into the public system.
Result renews expectations for patients without therapeutic alternatives
Patients with metastatic pancreatic cancer face limited options after chemotherapy failure.
The impact observed during the ASCO plenary session precisely reflected the magnitude of the results presented.
Oncologist Stephen Stefani, from the Americas Health Foundation, highlighted to g1 that the study combined survival gain, low toxicity, and an innovative mechanism for a historically difficult-to-treat disease.
Access to the medication will still depend on the next regulatory steps.
Data from the RASolute 302 study, however, reinforce an important change in a scenario that, for decades, offered few prospects for advancement for these patients.
In light of such significant results, could daraxonrasib inaugurate a new phase in the fight against metastatic pancreatic cancer?
Be the first to react!